165 related articles for article (PubMed ID: 34927279)
21. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
24. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
25. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
Doherty SD; Ni X; Doherty CB; Jones D; Zhao X; Owen LB; Duvic M
Arch Dermatol Res; 2006 Dec; 298(7):353-6. PubMed ID: 17021762
[TBL] [Abstract][Full Text] [Related]
26. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
27. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
Gaydosik AM; Queen DS; Trager MH; Akilov OE; Geskin LJ; Fuschiotti P
Blood; 2020 Oct; 136(15):1748-1759. PubMed ID: 32438399
[TBL] [Abstract][Full Text] [Related]
29. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.
Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654
[TBL] [Abstract][Full Text] [Related]
30. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
31. Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma.
Willerslev-Olsen A; Gjerdrum LMR; Lindahl LM; Buus TB; Pallesen EMH; Gluud M; Bzorek M; Nielsen BS; Kamstrup MR; Rittig AH; Bonefeld CM; Krejsgaard T; Geisler C; Koralov SB; Litman T; Becker JC; Woetmann A; Iversen L; Odum N
J Invest Dermatol; 2021 Oct; 141(10):2449-2458. PubMed ID: 33862068
[TBL] [Abstract][Full Text] [Related]
32. Mycosis fungoides and Sézary syndrome tumor cells express epidermal fatty acid-binding protein, whose expression decreases with loss of epidermotropism.
Takahashi-Shishido N; Sugaya M; Morimura S; Suga H; Oka T; Kamijo H; Miyagaki T; Sato S
J Dermatol; 2021 May; 48(5):685-689. PubMed ID: 33560534
[TBL] [Abstract][Full Text] [Related]
33. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
34. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.
Lee BN; Duvic M; Tang CK; Bueso-Ramos C; Estrov Z; Reuben JM
Clin Diagn Lab Immunol; 1999 Jan; 6(1):79-84. PubMed ID: 9874668
[TBL] [Abstract][Full Text] [Related]
35. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
Isufi I; Seropian S; Gowda L; Wilson LD; Roberts K; Girardi M; Perreault S; Foss F
Leuk Lymphoma; 2020 Dec; 61(12):2955-2961. PubMed ID: 32643494
[TBL] [Abstract][Full Text] [Related]
36. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
37. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
Olszewska B; Żawrocki A; Lakomy J; Karczewska J; Gleń J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
[TBL] [Abstract][Full Text] [Related]
38. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
39. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides and Sezary syndrome against a human immunodeficiency virus-positive background: case report.
Gahongayire F
Int J Dermatol; 2007 Oct; 46 Suppl 1():32-5. PubMed ID: 17919204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
